Skip to main content
Fig. 3 | Clinical Proteomics

Fig. 3

From: Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations

Fig. 3

Purification and characterization of a recombinant GP1 standard. a Representative chromatogram of preparative C4 reverse phase HPLC of 300 µg reduced recombinant GP material indicating fraction collection points. b SDS PAGE followed by silver-staining of fractions 1–7 showing the separation of GP1 (top arrow) and GP2 (bottom arrow). Material from fraction 1 was divided into 1.8 µg aliquots and used for quantitation standard. c Silver stained SDS PAGE performed under reducing conditions comparing the rGP starting material and the purified rGP1 standard. (top arrow) GP1 and (bottom arrow) GP2. D) Western blot of eVLP Lot ‘A’, eVLP Lot ‘E’, unpurified rGP and the purified rGP1 standard using the monoclonal antibody 6D8 showing the detection of fully glycosylated GP1 (arrow). E) Western blot of eVLP Lot ‘A’, eVLP Lot ‘E’, unpurified rGP and the purified rGP1 standard using the monoclonal antibody H3D5 showing the detection of fully glycosylated GP1 (arrow) and GP protein fragments

Back to article page

Clinical Proteomics

ISSN: 1559-0275